MUSTANG BIO, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that MUSTANG BIO, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($468.0K) | Nov 7, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($762.0K) | Aug 8, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($153.0K) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($1.41M) | Nov 7, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($8.20M) | Aug 8, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($5.19M) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($10.06M) | Nov 8, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($16.24M) | Aug 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($16.69M) | May 15, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($19.00M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($19.10M) | Aug 14, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($19.80M) | May 12, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($17.01M) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($14.36M) | Aug 11, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($14.96M) | May 12, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($12.95M) | Nov 12, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($14.60M) | Aug 16, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($11.86M) | May 14, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($10.17M) | Nov 6, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($10.40M) | Aug 10, 2020 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($624.0K) | Nov 7, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($885.0K) | Aug 8, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($253.0K) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($1.46M) | Nov 7, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($8.54M) | Aug 8, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($5.23M) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($10.31M) | Nov 8, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($13.89M) | Aug 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($16.32M) | May 15, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($18.85M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($18.24M) | Aug 14, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($19.64M) | May 12, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($17.08M) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($14.44M) | Aug 11, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($15.09M) | May 12, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($10.43M) | Nov 12, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($14.12M) | Aug 16, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($11.52M) | May 14, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($10.00M) | Nov 6, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($10.21M) | Aug 10, 2020 |